Associations - FLT3 mutation

FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	CA-4948 Sensitive: C3 – Early Trials EHA 2022 - 2 weeks (NewC3)	CA-4948 Sensitive: C3 – Early Trials EHA 2022 - 2 weeks - (New C3)
FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	CA-4948 Sensitive: C3 – Early Trials EHA 2022 - 2 weeks (NewC3)	CA-4948 Sensitive: C3 – Early Trials EHA 2022 - 2 weeks - (New C3)
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	HM43239 Sensitive: B - Late Trials Aptose Biosci Press Release - 3 weeks (NewB)	HM43239 Sensitive: B - Late Trials Aptose Biosci Press Release - 3 weeks - (New B)
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	gilteritinib Sensitive: A1 - Approval	gilteritinib Sensitive: A1 - Approval
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	midostaurin Sensitive: A1 - Approval	midostaurin Sensitive: A1 - Approval
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: A2 - Guideline	venetoclax Sensitive: A2 - Guideline
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	gemtuzumab ozogamicin Sensitive: A2 - Guideline	gemtuzumab ozogamicin Sensitive: A2 - Guideline
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 inhibitor Sensitive: B - Late Trials	FLT3 inhibitor Sensitive: B - Late Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax + azacitidine Sensitive: B - Late Trials	venetoclax + azacitidine Sensitive: B - Late Trials
FLT3 mutation FLT3 mutation	Leukemia Leukemia	FLT3 mutation FLT3 mutation	Leukemia Leukemia	midostaurin Sensitive: B - Late Trials	midostaurin Sensitive: B - Late Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	sunitinib Sensitive: C2 – Inclusion Criteria	sunitinib Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	quizartinib Sensitive: C2 – Inclusion Criteria	quizartinib Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria	Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	ARO-002 Sensitive: C2 – Inclusion Criteria	ARO-002 Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	CEP-701 Sensitive: C2 – Inclusion Criteria	CEP-701 Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	ARO-002 Sensitive: C2 – Inclusion Criteria	ARO-002 Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	sorafenib Sensitive: C2 – Inclusion Criteria	sorafenib Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	azacitidine Sensitive: C2 – Inclusion Criteria	azacitidine Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	quizartinib Sensitive: C2 – Inclusion Criteria	quizartinib Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Sensitive: C3 – Early Trials	venetoclax + midostaurin Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Sensitive: C3 – Early Trials	venetoclax + gilteritinib Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Sensitive: C3 – Early Trials	venetoclax + sorafenib Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Non Small Cell Lung Cancer NSCLC	FLT3 mutation FLT3 mutation	Non Small Cell Lung Cancer NSCLC	nintedanib Sensitive: C3 – Early Trials	nintedanib Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	ivosidenib Resistant: C3 – Early Trials	ivosidenib Resistant: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	cytarabine + clofarabine Sensitive: C3 – Early Trials	cytarabine + clofarabine Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	cytarabine + cladribine Sensitive: C3 – Early Trials	cytarabine + cladribine Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	decitabine + clofarabine Sensitive: C3 – Early Trials	decitabine + clofarabine Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	decitabine + cladribine Sensitive: C3 – Early Trials	decitabine + cladribine Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 inhibitor + venetoclax + decitabine Sensitive: C3 – Early Trials	FLT3 inhibitor + venetoclax + decitabine Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: C4 – Case Studies	cytarabine / daunorubicin liposomal formulation Sensitive: C4 – Case Studies
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	MEK inhibitor + FLT3 inhibitor Sensitive: D – Preclinical	MEK inhibitor + FLT3 inhibitor Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	sorafenib + LY3009120 Sensitive: D – Preclinical	sorafenib + LY3009120 Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	PF-02545920 Sensitive: D – Preclinical	PF-02545920 Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	5-fluorouracil Sensitive: D – Preclinical	5-fluorouracil Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	quizartinib + IACS-010759 Sensitive: D – Preclinical	quizartinib + IACS-010759 Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	AG-1296 Sensitive: D – Preclinical	AG-1296 Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Chronic Myeloid Leukemia CML	FLT3 mutation FLT3 mutation	Chronic Myeloid Leukemia CML	sunitinib Sensitive: D – Preclinical	sunitinib Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	SU5614 Sensitive: D – Preclinical	SU5614 Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	ASP7487 + NT-157 Sensitive: D – Preclinical	ASP7487 + NT-157 Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	venetoclax + olaparib Sensitive: D – Preclinical	venetoclax + olaparib Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	OTS167 Sensitive: D – Preclinical	OTS167 Sensitive: D – Preclinical
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	gilteritinib + ERAS-601 Sensitive: D – Preclinical	gilteritinib + ERAS-601 Sensitive: D – Preclinical